{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T02:45:09Z","timestamp":1790649909657,"version":"4.1.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,5,27]]},"DOI":"10.7759\/cureus.39553","type":"journal-article","created":{"date-parts":[[2023,5,27]],"date-time":"2023-05-27T07:44:39Z","timestamp":1685173479000},"source":"Crossref","is-referenced-by-count":6,"title":["Role of Anifrolumab in Refractory Cutaneous Manifestations of Lupus Erythematosus: A Case Series and Literature Review"],"prefix":"10.7759","author":[{"given":"Muhammad Atif","family":"Khan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faiza Humayun","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hina Benish","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constantine","family":"Saadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nichole","family":"Davey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1191\/0961203306lu2305xx","article-title":"Epidemiology of systemic lupus erythematosus: a comparison of worldwide disease burden","volume":"15","author":"Danchenko N","year":"2006","unstructured":"Danchenko N, Satia JA, Anthony MS. Epidemiology of systemic lupus erythematosus: a comparison of worldwide disease burden. Lupus. 2006, 15:308-318. 10.1191\/0961203306lu2305xx","journal-title":"Lupus"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0000000000000704","article-title":"Treatment of cutaneous lupus erythematosus: current approaches and future strategies","volume":"32","author":"Shi H","year":"2020","unstructured":"Shi H, Gudjonsson JE, Kahlenberg JM. Treatment of cutaneous lupus erythematosus: current approaches and future strategies. Curr Opin Rheumatol. 2020, 32:208-214. 10.1097\/BOR.0000000000000704","journal-title":"Curr Opin Rheumatol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1111\/j.0022-202X.2005.23889.x","article-title":"The CLASI (Cutaneous Lupus Erythematosus Disease Area and Severity Index): an outcome instrument for cutaneous lupus erythematosus","volume":"125","author":"Albrecht J","year":"2005","unstructured":"Albrecht J, Taylor L, Berlin JA, et al.. The CLASI (Cutaneous Lupus Erythematosus Disease Area and Severity Index): an outcome instrument for cutaneous lupus erythematosus. J Invest Dermatol. 2005, 125:889-894. 10.1111\/j.0022-202X.2005.23889.x","journal-title":"J Invest Dermatol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-215089","article-title":"2019 update of the EULAR recommendations for the management of systemic lupus erythematosus","volume":"78","author":"Fanouriakis A","year":"2019","unstructured":"Fanouriakis A, Kostopoulou M, Alunno A, et al.. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis. 2019, 78:736-745. 10.1136\/annrheumdis-2019-215089","journal-title":"Ann Rheum Dis"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1002\/art.30613","article-title":"A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus","volume":"63","author":"Furie R","year":"2011","unstructured":"Furie R, Petri M, Zamani O, et al.. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum. 2011, 63:3918-3930. 10.1002\/art.30613","journal-title":"Arthritis Rheum"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1912196","article-title":"Trial of anifrolumab in active systemic lupus erythematosus","volume":"382","author":"Morand EF","year":"2020","unstructured":"Morand EF, Furie R, Tanaka Y, et al.. Trial of anifrolumab in active systemic lupus erythematosus. N Engl J Med. 2020, 382:211-221. 10.1056\/NEJMoa1912196","journal-title":"N Engl J Med"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.537","article-title":"Tacrolimus 0.03% ointment in labial discoid lupus erythematosus: a randomized, controlled clinical trial","volume":"55","author":"Wang X","year":"2015","unstructured":"Wang X, Zhang L, Luo J, et al.. Tacrolimus 0.03% ointment in labial discoid lupus erythematosus: a randomized, controlled clinical trial. J Clin Pharmacol. 2015, 55:1221-1228. 10.1002\/jcph.537","journal-title":"J Clin Pharmacol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1007\/s11882-020-00906-8","article-title":"Cutaneous lupus erythematosus: progress and challenges","volume":"20","author":"Petty AJ","year":"2020","unstructured":"Petty AJ, Floyd L, Henderson C, Nicholas MW. Cutaneous lupus erythematosus: progress and challenges. Curr Allergy Asthma Rep. 2020, 20:12. 10.1007\/s11882-020-00906-8","journal-title":"Curr Allergy Asthma Rep"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1002\/art.40018","article-title":"Effects of hydroxychloroquine in patients with cutaneous lupus erythematosus: a multicenter, double-blind, randomized, parallel-group trial","volume":"69","author":"Yokogawa N","year":"2017","unstructured":"Yokogawa N, Eto H, Tanikawa A, et al.. Effects of hydroxychloroquine in patients with cutaneous lupus erythematosus: a multicenter, double-blind, randomized, parallel-group trial. Arthritis Rheumatol. 2017, 69:791-799. 10.1002\/art.40018","journal-title":"Arthritis Rheumatol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-016-0173-9","article-title":"Cutaneous lupus erythematosus: an update on pathogenesis, diagnosis and treatment","volume":"17","author":"Hejazi EZ","year":"2016","unstructured":"Hejazi EZ, Werth VP. Cutaneous lupus erythematosus: an update on pathogenesis, diagnosis and treatment. Am J Clin Dermatol. 2016, 17:135-146. 10.1007\/s40257-016-0173-9","journal-title":"Am J Clin Dermatol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.cytogfr.2007.10.006","article-title":"Plasmacytoid dendritic cells and type I IFN: 50 years of convergent history","volume":"19","author":"Fitzgerald-Bocarsly P","year":"2008","unstructured":"Fitzgerald-Bocarsly P, Dai J, Singh S. Plasmacytoid dendritic cells and type I IFN: 50 years of convergent history. Cytokine Growth Factor Rev. 2008, 19:3-19. 10.1016\/j.cytogfr.2007.10.006","journal-title":"Cytokine Growth Factor Rev"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2012.03.014","article-title":"JAK and STAT signaling molecules in immunoregulation and immune-mediated disease","volume":"36","author":"O'Shea JJ","year":"2012","unstructured":"O'Shea JJ, Plenge R. JAK and STAT signaling molecules in immunoregulation and immune-mediated disease. Immunity. 2012, 36:542-550. 10.1016\/j.immuni.2012.03.014","journal-title":"Immunity"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-10-1114","article-title":"Direct effects of type I interferons on cells of the immune system","volume":"17","author":"Hervas-Stubbs S","year":"2011","unstructured":"Hervas-Stubbs S, Perez-Gracia JL, Rouzaut A, Sanmamed MF, Le Bon A, Melero I. Direct effects of type I interferons on cells of the immune system. Clin Cancer Res. 2011, 17:2619-2627. 10.1158\/1078-0432.CCR-10-1114","journal-title":"Clin Cancer Res"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-019-1878-y","article-title":"High levels of circulating interferons type I, type II and type III associate with distinct clinical features of active systemic lupus erythematosus","volume":"21","author":"Oke V","year":"2019","unstructured":"Oke V, Gunnarsson I, Dorschner J, Eketj\u00e4ll S, Zickert A, Niewold TB, Svenungsson E. High levels of circulating interferons type I, type II and type III associate with distinct clinical features of active systemic lupus erythematosus. Arthritis Res Ther. 2019, 21:107. 10.1186\/s13075-019-1878-y","journal-title":"Arthritis Res Ther"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.6061\/clinics\/2012(02)11","article-title":"Clinical and serological manifestations associated with interferon-\u03b1 levels in childhood-onset systemic lupus erythematosus","volume":"67","author":"Postal M","year":"2012","unstructured":"Postal M, Sinicato NA, Peli\u00e7ari KO, Marini R, Lavras Costallat LT, Appenzeller S. Clinical and serological manifestations associated with interferon-\u03b1 levels in childhood-onset systemic lupus erythematosus. Clinics (Sao Paulo). 2012, 67:157-162. 10.6061\/clinics\/2012(02)11","journal-title":"Clinics (Sao Paulo)"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.41.754","article-title":"Lupus retinopathy associated with a high IFN-alpha level in the cerebrospinal fluid","volume":"41","author":"Kondo M","year":"2002","unstructured":"Kondo M, Murakawa Y, Sumita Y, Masuda H, Kobayashi S. Lupus retinopathy associated with a high IFN-alpha level in the cerebrospinal fluid. Intern Med. 2002, 41:754-756. 10.2169\/internalmedicine.41.754","journal-title":"Intern Med"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1186\/ar3514","article-title":"Replicated associations of TNFAIP3, TNIP1 and ETS1 with systemic lupus erythematosus in a southwestern Chinese population","volume":"13","author":"Zhong H","year":"2011","unstructured":"Zhong H, Li XL, Li M, et al.. Replicated associations of TNFAIP3, TNIP1 and ETS1 with systemic lupus erythematosus in a southwestern Chinese population. Arthritis Res Ther. 2011, 13:R186. 10.1186\/ar3514","journal-title":"Arthritis Res Ther"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1007\/s10753-014-9916-z","article-title":"Emerging role of SIGIRR rs7396562(T\/G) polymorphism in systemic lupus erythematosus in a Chinese population","volume":"37","author":"Zhu Y","year":"2014","unstructured":"Zhu Y, Wang DG, Yang XK, et al.. Emerging role of SIGIRR rs7396562(T\/G) polymorphism in systemic lupus erythematosus in a Chinese population. Inflammation. 2014, 37:1847-1851. 10.1007\/s10753-014-9916-z","journal-title":"Inflammation"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2018-000261","article-title":"Characterisation of anifrolumab, a fully human anti-interferon receptor antagonist antibody for the treatment of systemic lupus erythematosus","volume":"5","author":"Riggs JM","year":"2018","unstructured":"Riggs JM, Hanna RN, Rajan B, et al.. Characterisation of anifrolumab, a fully human anti-interferon receptor antagonist antibody for the treatment of systemic lupus erythematosus. Lupus Sci Med. 2018, 5:e000261. 10.1136\/lupus-2018-000261","journal-title":"Lupus Sci Med"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1002\/art.39962","article-title":"Anifrolumab, an anti-interferon-\u03b1 receptor monoclonal antibody, in moderate-to-severe systemic lupus erythematosus","volume":"69","author":"Furie R","year":"2017","unstructured":"Furie R, Khamashta M, Merrill JT, et al.. Anifrolumab, an anti-interferon-\u03b1 receptor monoclonal antibody, in moderate-to-severe systemic lupus erythematosus. Arthritis Rheumatol. 2017, 69:376-386. 10.1002\/art.39962","journal-title":"Arthritis Rheumatol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/151665-role-of-anifrolumab-in-refractory-cutaneous-manifestations-of-lupus-erythematosus-a-case-series-and-literature-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:03:49Z","timestamp":1707509029000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/151665-role-of-anifrolumab-in-refractory-cutaneous-manifestations-of-lupus-erythematosus-a-case-series-and-literature-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,27]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.39553","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5,27]]}}}